rs12101261 — TSHR TSHR Intron 1 Adjacent Regulatory Variant

Intronic regulatory variant in TSHR intron 1 that is the primary PLZF repressor-binding site in the open chromatin region controlling thymic TSHR expression; the T allele allows stronger PLZF binding, reduces intrathymic TSHR levels, impairs central immune tolerance to thyroid antigens, and confers susceptibility to Graves' disease

See your personal result for TSHR

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

TSHR Intron 1 — The PLZF Binding Site That Gates Thyroid Self-Tolerance

The thyroid stimulating hormone receptor (TSHR) is the defining autoantigen in Graves' disease — the most common autoimmune cause of hyperthyroidism. In Graves' disease, the immune system generates stimulating autoantibodies (TRAbs) that lock onto TSHR and permanently mimic the pituitary's TSH signal, driving uncontrolled thyroid hormone production. Understanding why these autoantibodies arise requires looking inside the thymus, where the immune system learns to distinguish self from non-self.

rs12101261 sits in intron 1 of TSHR within an [open chromatin regulatory region | A stretch of DNA accessible to transcription factors and regulatory proteins, indicating active gene regulation at this location] that controls TSHR expression in thymic epithelial cells. It is immediately adjacent to rs12101255, the more widely studied tag SNP for this locus — but the Stefan et al. PNAS 2014 mechanistic study11 Stefan et al. PNAS 2014 mechanistic study
PMID 25122677 revealed that rs12101261 is the primary binding site for the transcriptional repressor PLZF, making it the functional heart of the Graves' susceptibility signal at this region.

The Mechanism

Within the intron 1 regulatory element, the transcriptional repressor [PLZF | Promyelocytic leukemia zinc finger protein; a transcription factor that recruits histone deacetylase complexes to silence gene expression] binds preferentially and more strongly to the disease-associated T allele at rs12101261. The C allele shows weaker PLZF affinity. When PLZF is bound — especially during interferon-alpha signalling triggered by viral infection, which enhances [H3K4me1 histone enrichment | A histone modification mark associated with active enhancer elements; its enrichment here during IFNα stimulation indicates epigenetic activation of the regulatory region] at this site — TSHR gene expression in thymic epithelial cells is suppressed.

The functional consequence is measurable in human thymus: Stefan et al.22 Stefan et al.
Genetic-epigenetic dysregulation of thymic TSH receptor gene expression triggers thyroid autoimmunity. PNAS 2014;111:12562–7 showed that TT homozygotes have a median thymic TSHR expression of 2.06 units versus 7.09 units in CT+CC carriers (P = 0.01) — a 3.4-fold reduction. Lower thymic TSHR means fewer TSHR-presenting thymic cells, which means autoreactive T cells that target TSHR escape the clonal deletion checkpoint and persist in the circulation. These escaped cells are the seed of the Graves' autoimmune response, awaiting an environmental trigger to activate them fully.

Viral infection is particularly potent as a trigger precisely because IFNα amplifies PLZF-mediated TSHR repression at this locus — creating a direct mechanistic link between common respiratory and enteric viral infections and Graves' disease onset in susceptible carriers.

The Evidence

rs12101261 was confirmed as an independent Graves' disease susceptibility variant in a large refined association study of 5,368 GD patients and 4,942 controls in the Chinese Han population33 5,368 GD patients and 4,942 controls in the Chinese Han population
Liu et al. European Journal of Endocrinology 2014; PMID 24144966. Using regression analysis of 74 genotyped and 922 imputed SNPs, rs12101261 and rs179243 emerged as the probable causal variants at the TSHR locus. Critically, GD patients carrying the susceptible rs12101261 genotype had significantly higher rates of persistent TRAb positivity after more than one year of treatment — meaning the variant predicts not just disease onset but also treatment resistance, a clinically actionable finding for patients choosing between antithyroid drugs, radioiodine, and thyroidectomy.

A 2019 haplotype study in 1,217 Chinese Han subjects (Sun et al. Int J Genomics 201944 Sun et al. Int J Genomics 2019
PMID 31565653) confirmed the C allele at rs12101261 as negatively correlated with GD. The protective GGCG haplotype (including C at rs12101261) showed OR = 0.56 (95% CI 0.46–0.67, P < 0.001) — the strongest haplotype-level protective signal at this locus.

The PLZF binding data from Stefan 2014 establishes the molecular basis for the association: this is not simply a tag SNP in linkage disequilibrium with a distant causal variant — the T allele itself is the biochemically active element that drives reduced thymic TSHR expression.

Practical Actions

TT homozygotes show ~3.4-fold reduced thymic TSHR expression compared with protective carriers, the largest effect size demonstrated at the molecular level for this locus. The clinical priority is early recognition of hyperthyroid symptoms and awareness of the viral trigger pathway. Establishing a baseline thyroid antibody panel before symptoms appear captures the pre-clinical window when TRAbs first appear.

Selenium at 100–200 mcg/day as selenomethionine has RCT-level evidence for reducing TRAb titres and autoimmune thyroid activity. Excess iodine is a documented Graves' disease precipitant and should be avoided in susceptible carriers. Given the finding that susceptible rs12101261 genotypes associate with persistent TRAb positivity after treatment, TT carriers who do develop Graves' disease may be stronger candidates for definitive treatment (radioiodine or thyroidectomy) over long-term antithyroid drug therapy — a conversation to have with an endocrinologist if GD is diagnosed.

Interactions

rs12101261 and rs12101255 share the same open chromatin regulatory element in TSHR intron 1 and are in strong linkage disequilibrium. rs12101261 appears to be the primary functional variant (the direct PLZF-binding site), while rs12101255 was historically studied first as the tag SNP. Together, they define the same Graves' susceptibility haplotype. rs179247, located ~18 kb upstream, is a third TSHR intron 1 variant in the same risk haplotype block.

Beyond the TSHR locus, Graves' disease has additional independent susceptibility loci: CTLA4 variants (rs3087243, rs231775) impair T-cell immune checkpoint function through an entirely separate mechanism; PTPN22 R620W (rs2476601) lowers T-cell activation thresholds. Carriers of multiple Graves' risk variants across these independent loci carry substantially higher cumulative susceptibility than any single locus predicts.

Genotype Interpretations

What each possible genotype means for this variant.

CC Protective Genotype Normal

Both copies of the protective C allele — thymic TSHR tolerance unaffected at this locus

You carry two copies of the C allele at rs12101261 — the lower-risk genotype at the primary PLZF-binding site in the TSHR intron 1 regulatory region. Approximately 36% of people globally share this genotype (slightly more common among Europeans and South Asians). The C allele binds the PLZF repressor weakly, so your thymic expression of the TSH receptor is not suppressed at this locus. This means the immune system's central tolerance training for TSHR proceeds normally here, reducing the probability that autoreactive T cells escape deletion. rs12101261 does not add Graves' disease susceptibility for you, though other genetic and environmental factors still contribute overall.

CT One Risk Allele Intermediate

One T risk allele — intermediate PLZF-binding activity and modestly elevated Graves' risk

The codominant inheritance pattern at this locus means CT carriers have intermediate thymic TSHR suppression. Absolute lifetime Graves' disease risk from this single variant remains modest — roughly 1–2% of women and 0.1–0.2% of men develop Graves' disease across their lifetime at baseline, and rs12101261 CT carriage shifts this modestly upward.

The clinically important feature of this variant is its connection to the viral trigger pathway: IFNα (released during viral infections) enhances PLZF binding specifically at the T allele in the intron 1 regulatory region, acutely reducing thymic TSHR expression during infection windows. This provides a mechanistic explanation for the well-documented observation that Graves' disease often follows viral illness in genetically susceptible individuals.

TT Two Risk Alleles High Risk

Two T risk alleles — maximum PLZF-binding activity, ~3.4-fold reduced thymic TSHR expression, highest Graves' risk

The TT genotype creates the worst-case regulatory configuration at this locus: both alleles present strong PLZF-binding sites, and both are maximally sensitive to IFNα-driven epigenetic enhancement of PLZF binding during viral infections. This means during any viral illness — common respiratory or enteric infections included — your thymic TSHR expression may be acutely and substantially suppressed, expanding the window during which autoreactive T cells escape tolerance training.

The finding that TT carriers have persistently elevated TRAb after treatment carries practical clinical weight: standard guidance for Graves' disease remission using antithyroid drugs (methimazole, carbimazole) relies on TRAb normalisation within 12–18 months as the indicator for attempting drug discontinuation. If TRAb remains positive — as seen more often with susceptible rs12101261 genotypes — the probability of disease relapse after stopping antithyroid drugs is substantially higher. TT carriers who develop Graves' disease may be stronger candidates for definitive treatment (radioiodine ablation or thyroidectomy) over prolonged antithyroid drug courses.

Graves' disease untreated or undertreated carries secondary risks: atrial fibrillation from sustained cardiac effects of thyroid hormone excess, and osteoporosis from thyroid hormone's osteolytic activity. Early detection and definitive treatment limit these downstream complications.